Actively Recruiting
Deferoxamine In the Treatment of Aneurysmal Subarachnoid Hemorrhage (DISH)
Led by Aditya S. Pandey, MD · Updated on 2025-11-28
120
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Aneurysmal subarachnoid hemorrhage (aSAH) is a serious condition with high risk of death and complications shortly after onset. This trial investigates the safety and effectiveness of deferoxamine mesylate (DFO), a drug that binds free iron to prevent brain injury caused by iron-related damage. Researchers aim to understand if DFO can improve outcomes for patients admitted with aSAH at the University of Michigan. Participants will be randomly assigned to receive one of two doses of intravenous deferoxamine (32 mg/kg or 48 mg/kg) or a placebo (normal saline). The treatment involves three doses administered over three days, each given 24 hours apart at a fixed rate. The trial includes a double-blind design where neither participants nor researchers know the assigned treatment to ensure unbiased results. During the study, patients will be monitored closely with assessments including the Utility-weighted modified Rankin Scale at six months after hospital discharge to measure recovery. Additional evaluations such as cognitive tests, oxygen levels, and brain complication checks will occur during and after treatment. Information will be collected for up to six months post-discharge to understand the long-term effects and safety of the treatments.
CONDITIONS
Brief Title
Deferoxamine In the Treatment of Aneurysmal Subarachnoid Hemorrhage (aSAH)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Aneurysmal subarachnoid hemorrhage confirmed by vascular imaging
- Aneurysm treated with endovascular or microsurgical intervention
- Hunt-Hess score of 4 or less
- Modified Fisher Grade I to IV
- Glasgow Coma Scale 7 or higher after External Ventricular Drain placement if needed
- First dose of study drug can be given within 24 hours of symptom onset
- Functional independence before hemorrhage, Modified Rankin Scale 1 or less
- Informed consent given by patient or legal authorized representative
You will not qualify if you...
- Previous hypersensitivity to or treatment with deferoxamine
- Presence of giant aneurysm larger than 25 mm
- Severe iron deficiency anemia with hemoglobin 7 g/dL or less or transfusion dependent
- Irreversibly impaired brainstem function
- Abnormal kidney function with serum creatinine over 2 mg/dL
- Pre-existing severe disability, Modified Rankin Scale 2 or more
- Coagulopathy or use of anti-platelet or anticoagulant drugs
- Severe hearing loss
- Chronic pulmonary disease limiting daily activities or requiring home oxygen
- Acute pulmonary disease needing high oxygen support in prior 72 hours
- Taking iron supplements with more than 325 mg of ferrous iron
- Pregnancy or nursing
- Life expectancy less than 90 days from other health problems
- Participation in another experimental therapy trial (observational studies allowed)
- Prior liver dysfunction
- Known low blood cell counts (platelets less than 50,000, neutrophils less than 500)
- Current use of prochlorperazine
- History of severe psychiatric disorder
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 3 days
Participants receive three intravenous doses of Deferoxamine or placebo over three consecutive days.
3 visits (in-person) on days 1, 2, and 3
Duration - Up to 6 months after hospital discharge
Participants are monitored for safety and outcomes including cognitive assessment and cerebrospinal fluid diversion up to 6 months after hospital discharge.
Visits at hospital discharge (approximately 3-4 weeks) and at 6 months
Trial Site Locations
Total: 1 location
1
University of Michigan
Ann Arbor, Michigan, United States, 48109
Actively Recruiting
Research Team
S
Sravanthi Koduri
A
Aditya Pandey, MD
How is the study designed?
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
3
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here